IL-NIQ
NIQ, the global leader in consumer intelligence, is pleased to announce the NIQ Connect platform capabilities have now expanded to use Snowflake Secure Data Sharing. This capability marks a significant milestone for NIQ's Connect platform, empowering customers in 84 global markets with enhanced data-sharing capabilities and seamless real-time data access. As a result, this can eliminate processing and loading wait times, delivering unparalleled efficiency and agility in a complex consumer landscape.
“By extending their ability to effortlessly access global, omnichannel data, we can empower clients to uncover new pathways to growth even within a very complex consumer landscape,” said Troy Treangen, Chief Product Officer at NIQ. “Innovation is our compass, and our commitment to reengineering the Connect platform has charted a new course. Our strategic investments have allowed us to unlock the power of modern data sharing capabilities, guiding our clients towards a brighter, data-driven future."
NIQ Connect is a crucial asset for enterprises, enabling them to harness their data across all facets of their organization. With integrated data assets, businesses can readily identify emerging trends, pinpoint performance gaps, and respond swiftly to growth opportunities. This global collaboration is poised to unveil novel insights, leading to a deeper understanding of customers' behavior and preferences.
Additional highlights of the NIQ’s Connect platform integration with Snowflake’s Retail Data Cloud include:
- Seamless Data Integration: Companies will benefit from the seamless integration of NIQ's rich consumer and market data into Snowflake’s environment. This integration simplifies access to vast data sources, and drives significant speed improvements for our clients when accessing data.
- Secure Data Sharing: Availability through Snowflake facilitates near real-time data sharing, enabling businesses to access and query NIQ's data instantaneously. This dynamic exchange of information empowers organizations to stay ahead in today's fast-paced business landscape.
- Scalability and Flexibility: NIQ’s Connect platform with Snowflake Secure Data Sharing is designed to scale effortlessly with the growing data needs of businesses. Whether a company is a startup or a Fortune 500 enterprise, this provides the flexibility to adapt and grow in a rapidly changing environment.
- Enhanced AI and Machine Learning Capabilities: Businesses can leverage advanced analytics and machine learning within Snowflake's platform to derive actionable insights from NIQ's data. This synergy fosters innovation, enabling companies to make data-driven decisions with precision.
- Data Security and Compliance: Both NIQ and Snowflake prioritize data security and compliance. The joint solution ensures that sensitive data is protected providing peace of mind to businesses and their customers while enabling them to meet evolving regulatory requirements.
“NIQ is committed to helping companies become more agile at a time when being able to move quickly based on accurate data is paramount,” Treangen added. “This innovative data-sharing approach will provide Connect customers a competitive advantage today and be better prepared for the future. We are modernizing every level of our Connect platform, and we are excited about the enhancements to help our clients thrive.”
“As an incumbent leader in retail and consumer insights, NIQ has been a staple in the retail industry for delivering data that give a competitive edge to retailers and consumer product companies,” said Rosemary DeAragon, Global Head of Retail and Consumer Goods at Snowflake. “We are so excited to bring together the full power of the Snowflake Retail Data Cloud and the NIQ Connect platform, allowing global frictionless access to critical data through Snowflake data sharing.”
NIQ is dedicated to fostering innovation and enabling organizations to thrive in a data-driven world. The collaboration between NIQ and Snowflake represents a transformative step in the world of data sharing and will shape the future of data analytics. As organizations increasingly recognize the value of data in their operations, allowing them to exchange insights seamlessly and efficiently will empower them to unlock new opportunities and navigate the data landscape with ease.
For more information about this NIQ Connect and its benefits, please visit https://nielseniq.com/global/en/solutions/nielseniq-connect/.
About NIQ
NIQ is the world’s leading consumer intelligence company, delivering the most complete understanding of consumer buying behavior and revealing new pathways to growth. In 2023, NIQ combined with GfK, bringing together the two industry leaders with unparalleled global reach. With a holistic retail read and the most comprehensive consumer insights—delivered with advanced analytics through state-of-the-art platforms—NIQ delivers the Full ViewTM.
NIQ, is an Advent International portfolio company with operations in 100+ markets, covering more than 90% of the world’s population. For more information, visit NIQ.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230919644465/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom